Product Description
AZD1236 is a potent and reversible inhibitor of human MMP-9 and MMP-12 (IC50 = 4.5 and 6.1nM, respectively), with >10-fold selectivity to MMP-2 and MMP-13 and >350-fold selectivity to other members of the enzyme family. AZD1236 activity is approximately 20 to 50-fold lower at the rat, mouse, and guinea pig orthologues. In acute models of lung injury, AZD1236 inhibited the haemorrhage and inflammation induced by instillation of human MMP-12 into rat lungs by ~80% at 0.81mg/kg, and also abolished macrophage infiltration into BAL fluid induced by tobacco smoke inhalation in the mouse. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd1236.html)
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystic Fibrosis|Chronic Obstructive Pulmonary Disease
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00767052 |
D4260C00006 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-18 |
Treatments |
|
NCT01007929 |
D4260C00010 | P1 |
Terminated |
Healthy Volunteers |
None |
2025-08-27 |
Primary Endpoints|Treatments |
|
2008-004699-34 |
CYBER | P2 |
Terminated |
Cystic Fibrosis |
2009-08-28 |
2022-03-12 |
Treatments |
|
2008-002151-25 |
BICO | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-08-20 |
2022-03-12 |
Treatments |
|
2008-002230-30 |
2008-002230-30 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-07-21 |
2022-03-12 |
Treatments |
|
NCT00758706 |
BICO | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-05-01 |
2019-03-18 |
Treatments |
|
NCT00812045 |
CYBER | P2 |
Withdrawn |
Cystic Fibrosis |
None |
2019-03-18 |
Treatments |
|
NCT00758459 |
CERA | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
None |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/20/2022 |
News Article |
Birmingham research brings hope for spinal cord injury treatment |